PHOENIX, (Oct. 1, 2026) – Institutional Property Advisors (IPA), a division of Marcus & Millichap (NYSE: MMI) dedicated to serving the company’s institutional clients, announced today the sale of The Astor at Osborn, a 191-unit, mid-rise multifamily asset in Phoenix, Arizona. The property sold for $47.8 million, or $250,262 per unit.

“One of only two multifamily properties delivered along 7th Avenue since 1985, The Astor at Osborn benefits from a meaningful rent vs. own affordability gap,” said Steve Gebing, IPA executive managing director investments.” Within a one-mile radius, rents are 48% below the cost of homeownership.” Gebing and Cliff David, IPA executive managing director investments, represented the seller and procured the buyer.

The property has direct access to 171,000 employees within Midtown and Downtown Phoenix’s Innovation Corridor, which is populated by industry leading companies, including Dignity Health, Banner Health, UnitedHealth Group, and Freeport McMoRan. The Park Central Innovation Hub is nearby and IBM, U-Haul International, and CopperPoint Insurance Companies are within proximity. Shopping is nearby at the Uptown Plaza open-air shopping center, and the Phoenix Country Club is within a short drive.

Completed in 2019, The Astor at Osborn has garage parking, a resort-style swimming pool, fitness center, club room, and outdoor grilling stations. The unit mix ranges from studios to one-, two- and three-bedroom apartments. Units have nine- and 10-foot ceilings, pantries, stainless-steel appliances, and custom cabinetry.

In just five years, what began as a specialized donor testing laboratory at the UA Tech Park has evolved into a globally recognized operation supporting cell and tissue-based innovations across six continents.

 TUCSON, Ariz. (Oct. 1, 2026) – Eurofins CellTx, LLC, a specialized testing laboratory located at the UA Tech Park, has expanded its service offerings to provide comprehensive quality and functional assessment of human cell and tissue products, positioning the company to support the next generation of regenerative medicine, biotherapies, and reproductive health applications worldwide.

Founded in 2021, Eurofins CellTx was established to focus on donor eligibility testing for living donor human cells, tissues, and cellular and tissue-based products, including stem cells, cord blood, bone marrow, reproductive cells, and perinatal tissues. In just five years, the Tucson-based operation, part of the global network of Eurofins laboratories, has grown into a state-of-the-art testing facility supporting organizations across six continents. Today, Eurofins CellTx combines scientific expertise, rapid turnaround times, and a commitment to quality through compliance with FDA, CLIA, ISO 15189, and current Good Manufacturing Practice (cGMP) standards.

As the company enters its fifth year of operations, Eurofins CellTx is expanding its mission to address a growing need within the cell and reproductive fertility industries: evaluating not only the safety of cell and tissue products, but also their quality, integrity, and functional performance. This evolution builds upon the laboratory’s longstanding foundation in donor eligibility and safety testing while providing clients with deeper insights into the quality and functionality of cell and tissue products. The expanded capabilities are designed to support informed decision-making and ultimately contribute to improved patient outcomes.

This enhanced service portfolio supports a broader strategy designed to strengthen donor selection and source material evaluation for cell and biotherapies, as well as reproductive and fertility applications. By combining scientific expertise, rapid turnaround times, and regulatory excellence, Eurofins CellTx helps clients accelerate donor qualification, streamline processes, and minimize delays in product release and treatment.

The laboratory recently achieved cGMP accreditation, further demonstrating its commitment to quality, consistency, and patient safety. The accreditation reflects the implementation of rigorous systems, controls, documentation, and oversight designed to ensure reliable and reproducible testing services while meeting regulatory expectations for clinical and commercial programs. As advanced therapies continue to transform healthcare, these quality systems provide an important foundation for organizations developing innovative treatments and bringing them to patients worldwide.

The company’s name itself reflects that mission. While “Cell” represents the laboratory’s focus on human cell and tissue products, “Tx” symbolizes the ultimate purpose of those donations and therapies. Whether through transplantation, treatment, therapy, transfer, or transfusion, Eurofins CellTx supports the critical pathway that enables donated cells and tissues to reach patients in need.

Located within the UA Tech Park’s innovation ecosystem, Eurofins CellTx continues to play an important role in supporting the rapidly growing life sciences sector in Southern Arizona while serving clients and healthcare innovators across the globe. Through continued collaboration with industry partners, researchers and healthcare professionals, the company is expanding its capabilities to support the development of safe, high-quality therapies that have the potential to improve lives across the globe.

“Tolleson is seeing significant new residential and retail development, bringing more families to the area and supporting continued demand for childcare and early learning,” said Eric Garske, senior director investments. “The buyer already owned another Sunrise Schools property and recognized both the strength of the operator and the long-term need for these services in this growing market.”